Dr Chris Watson
Dr Chris Watson joined UCD as a Newman Scholar in 2006 and is the Principal Investigator of the Experimental & Clinical Cardiology Group based in the Conway Institute, UCD. The focus of this research group includes in vitro and in vivo models of hypertensive heart disease and diabetes to investigate the impact of novel anti-inflammatory and epigenetic modifying therapies targeting diseases such as cardiac fibrosis and hypertrophy. These activities also include a 5 year HRB research program to identify novel protein and miRNA biomarkers that could be used to risk stratify diabetic patients and predict future development of cardiovascular disease complications.
Dr Watson is a co-founder and co-Director of the UCD Global Health Research group (www.ghealthresearch.org) which is a multidisciplinary group of researchers seeking innovative methods of managing illness, particularly in low and middle income countries using emerging strategies of biomarker science, mHealth and health care system reform. Currently the gHealth Research group is working in Malawi, Uganda, UK and the US. Dr Watson has recently secured funding from Bill & Melinda Gates Foundation, November 2015.
Dr Watson is also a co-Principal Investigator for the Chronic Cardiovascular Disease Management group based in St. Vincents University Hospital, which recently published the STOP-HF trial (JAMA 2013) highlighting the utility of natriuretic peptides to identify patients as a risk stratifying tool for cardiovascular disease complications. This study has now expanded to focus on a Diabetic population within the community (Midland Project). In addition, Dr Watson is the Translational Research coordinator for the Heartbeat Trust (www.heartbeattrust.org).
Dr Watson is a steering committee member for the Irish Heart Foundation developed National Cardiovascular and Stroke Research Network. He is also actively involved in 3 on-going FP7 projects, one of which he is a co-Principle Investigator (FIBROTARGETS, HOMAGE, MEDIA). Dr Watson is involved in a number of innovation and commercialisation activities funded by Enterprise Ireland around novel diagnostic biomarkers for disease and novel therapeutic strategies.
From an educational perspective, Dr Watson has recently completed a Postgraduate Diploma in University Teaching & Learning at UCD, and has co-developed and is running the innovative UCD LabView initiative (http://www.ucd.ie/medicine/labview).
Dr Chris Watson is the principle investigator of the Experimental & Clinical Cardiology Group, co-Director of the gHealth Research group, and co-investigator of the SVUH Chronic Cardiovascular Disease Management Group (led by Prof Ken McDonald). Dr Chris Watson is based at UCD Conway Institute and has research interests in heart disease and the impact that cardiovascular risk factors such as diabetes, obesity, and hypertension have on cardiac fibrosis, heart failure, and diabetic cardiomyopathy. He is actively involved in novel biomarker and therapeutic research programmes. Dr Watson also has a keen interest in developing novel global health strategies for non-communicable diseases in low and middle income countries, focusing on remote diagnostics and eHealth/mHealth approaches in primary care settings.
| Cardiovascular disease
Biomarkers (cardiac tissue and circulating) - protein and miRNA
Epigenetics- DNA methylation
Novel therapeutics - targeting inflammation; monocyte and platelet activity; epigenetics
eHealth and mHealth
Global Health (www.ghealthresearch.org)
| Sponsor : Health Research Board (HRB)
Title : Natural History of Diabetic Cardiomyopathy
Start Date / End Date : 01-DEC-12 / 30-NOV-17
| Sponsor : Enterprise Ireland (EI)
Title : DNA METHYLATION INHIBITORS AS A NOVEL TREATMENT FOR CARDIAC AND LUNG FIBROSIS
Start Date / End Date : 12-OCT-12 / 31-DEC-12
| Sponsor : Health Research Board (HRB)
Title : Immunomodulatory-matrix metalloproteinase (MMP) inhibition with tetracyclines in obesity, diabetes and asymptomatic left ventricular diastolic dysfunction: impact on MMP-9 levels and cardiovascular structure and function
Start Date / End Date : 01-NOV-12 / 31-DEC-16
| Sponsor : EC Framework (FP7)
Title : Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)
Start Date / End Date : 01-SEP-13 / 31-AUG-17
| Sponsor : University College Dublin (UCD)
Title : CDA for Horizon 2020 grant support: Global Alliance for Chronic Diseases - prevention and treatment of type 2 diabetes (Horizon 2020, funding topic HC05-2014). EU project name: MTIMA ¿ Managing Type 2 diabetes In MAlawi
Start Date / End Date : 01-APR-14 / 30-SEP-15
| Sponsor : University College Dublin (UCD)
Title : School Funded Research Account
Start Date / End Date : 01-APR-14 / 30-SEP-15
| Sponsor : Enterprise Ireland (EI)
Title : Epigenetic therapy for the treatment of hypertrophic cardiomyopathies
Start Date / End Date : 18-AUG-14 / 17-AUG-15
| Sponsor : University College Dublin Foundation Ltd.
Title : research into global health
Start Date / End Date : 01-JUL-15 / 30-JUN-18
Project 1: The role of DNA methylation in the development of cardiac and lung fibrosis.
Project 2: A role for MMP inhibition in the prevention and treatment of heart failure.
Project 3: The role of SAP in the prevention and treatment of hypertensive heart disease and heart failure with preserved ejection fraction.
2012-current Co-supervision of three MSc students University College Dublin, School of Medicine and Medical Science
Project 1: Investigating the functional impact of novel circulating miRNA biomarkers for diabetic
Project 2: Detection of novel cardiac fibrosis related proteins and identify their role in disease.
Project 2: Development of a multiplexed biomarker assay for the screening of heart failure patients.
2013-current Co-supervision of one MD student
University College Dublin, School of Medicine and Medical Science
Project 1: Clinical Prediction Rules in the Diagnosis of Stage A and B Heart Failure.
Peer Reviewed Journals
|Watson C, James S;O'Connell E;Gallagher J;O'Reilly J;Tallon E;Baugh J;O'Connell J;O'Shea D;Ledwidge M;McDonald K (2016) 'Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure'. Biomarkers, :1-6. [DOI] [Details]|
|Murtagh G, Lyons T;O'Connell E;Ballot J;Geraghty L;Fennelly D;Gullo G;Ledwidge M;Crown J;Gallagher J;Watson C;McDonald KM;Walshe JM (2016) 'Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up'. Breast Cancer Research and Treatment, 156 (3):501-506. [DOI] [Details]|
|Glezeva, N. and Gallagher, J. and Ledwidge, M. and O'Donoghue, J. and Mcdonald, K. and Chipolombwe, J. and Watson, C. (2015) 'Heart failure in sub-Saharan Africa: Review of the aetiology of heart failure and the role of point-of-care biomarker diagnostics'. Tropical Medicine and International Health, . [DOI] [Details]|
|Horgan SJ, Watson CJ;Glezeva N;Collier P;Neary R;Tea IJ;Corrigan N;Ledwidge M;McDonald K;Baugh JA (2015) 'Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease'. Journal of Cardiovascular Translational Research, 8 (9):554-566. [DOI] [Details]|
|Glezeva N, Voon V;Watson C;Horgan S;McDonald K;Ledwidge M;Baugh J (2015) 'Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis'. Journal of Cardiac Failure, 21 (2):167-177. [DOI] [Details]|
|Neary R, Watson CJ;Baugh JA (2015) 'Epigenetics and the overhealing wound: the role of DNA methylation in fibrosis'. Fibrogenesis and Tissue Repair, 8 . [DOI] [Details]|
|Murtagh G, O Connell J;O Connell E;Tallon E;Watson C;Gallagher J;Baugh J;Patle A;O Connell L;Griffin J;O'Hanlon R;Voon V;Ledwidge M;O Shea D;McDonald K (2015) 'Importance of risk factor management in diabetic patients and reduction in Stage B heart failure'. Qjm-An International Journal Of Medicine, 108 (4):307-314. [DOI] [Details]|
|James S, Barton D;O'Connell E;Voon V;Murtagh G;Watson C;Murphy T;Prendiville B;Brennan D;Hensey M;O'Neill L;O'Hanlon R;Waterhouse D;Ledwidge M;Gallagher J;McDonald K (2015) 'Life expectancy for community-based patients with heart failure from time of diagnosis'. International Journal of Cardiology, 178 :268-274. [DOI] [Details]|
|Ledwidge MT, O'Connell E;Gallagher J;Tilson L;James S;Voon V;Bermingham M;Tallon E;Watson C;O'Hanlon R;Barry M;McDonald K (2015) 'Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study'. European Journal of Heart Failure, 17 (7):672-679. [DOI] [Details]|
|Watson CJ, Gupta SK;O'Connell E;Thum S;Glezeva N;Fendrich J;Gallagher J;Ledwidge M;Grote-Levi L;McDonald K;Thum T (2015) 'MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure'. European Journal of Heart Failure, 17 (4):405-415. [DOI] [Details]|
|Watson CJ, Horgan S;Neary R;Glezeva N;Tea I;Corrigan N;McDonald K;Ledwidge M;Baugh J (2015) 'Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis'. Journal of Cardiovascular Pharmacology and Therapeutics, . [DOI] [Details]|
|McDonald, K. and Ledwidge, M. and Gallagher, J. and Watson, C. (2015) 'Biomarker testing and pre-emptive therapy in preventing heart failure'. Current Cardiovascular Risk Reports, 9 (6). [DOI] [Details]|
|Dowling, D. and Corrigan, N. and Horgan, S. and Watson, C.J. and Baugh, J. and Downey, P. and McAuliffe, F.M. (2014) 'Cardiomyopathy in offspring of pregestational diabetic mouse pregnancy'. Journal of Diabetes Research, 2014 . [DOI] [Details]|
|Horgan S, Watson C;Glezeva N;Baugh J (2014) 'Murine models of diastolic dysfunction and heart failure with preserved ejection fraction'. Journal of Cardiac Failure, 20 (12):984-995. [DOI] [Details]|
|Murtagh G, O Connell J, O Connell E, Tallon E, Watson C, Gallagher J, Baugh J, Patle A, O Connell L, Griffin J, O' Hanlon R, Voon V, Ledwidge M, O Shea D, McDonald K (2014) 'Importance of Risk Factor Management in Diabetic Patients & Reduction in Stage B Heart Failure'. Quarterly Journal of Medicine, . [Details]|
|Watson, C.J. and Phelan, D. and Collier, P. and Horgan, S. and Glezeva, N. and Cooke, G. and Xu, M. and Ledwidge, M. and Mcdonald, K. and Baugh, J.A. (2014) 'Extracellular matrix sub-types and mechanical stretch impact human cardiac fibroblast responses to transforming growth factor beta'. Connective Tissue Research, 55 (3):248-256. [DOI] [Details]|
|Watson, C.J. and Collier, P. and Tea, I. and Neary, R. and Watson, J.A. and Robinson, C. and Phelan, D. and Ledwidge, M.T. and Mcdonald, K.M. and Mccann, A. and Sharaf, O. and Baugh, J.A. (2014) 'Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype'. Human Molecular Genetics, 23 (8):2176-2188. [DOI] [Details]|
|Glezeva N, Collier P, Voon V, Ledwidge M, McDonald K, Watson C, Baugh J (2013) 'Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide'. Journal of cardiovascular translational research, 6 (4):545-557. [DOI] [Details]|
|Ledwidge M, Gallagher J;Conlon C;Tallon E;O'Connell E;Dawkins I;Watson C;O'Hanlon R;Bermingham M;Patle A;Badabhagni MR;Murtagh G;Voon V;Tilson L;Barry M;McDonald L;Maurer B;McDonald K (2013) 'Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial'. Journal of the American Medical Association (JAMA), 310 (1):66-74. [DOI] [Details]|
|Jan A, Dawkins I, Murphy N, Collier P, Baugh J, Ledwidge M, McDonald K, Watson CJ. (2013) 'Associates of an elevated natriuretic peptide level in stable heart failure patients; implications for targeted management'. Scientific World Journal, . [Details]|
|Cooke, G., Govender, P., Watson, C. J., Armstrong, M. E., Keane, M. P., King, R., Tynan, A., Dunn, M., Donnelly, S. C. (2013) 'Sarcoidosis, Alveolar beta-Actin&Pulmonary Fibrosis'. Qjm-An International Journal Of Medicine, . [DOI] [Details]|
|Abulhul E, McDonald K, Martos R, Phelan D, Spiers JP, Hennessy M, Baugh J, Watson C, O'Loughlin C, Ledwidge M (2012) 'Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide'. Clinical Therapeutics, 34 (1):91-100. [DOI] [Details]|
|Phelan D, Watson C;Martos R;Collier P;Patle A;Donnelly S;Ledwidge M;Baugh J;McDonald K (2012) 'Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes'. PLoS ONE, 7 (11). [DOI] [Details]|
|Collier, P,Watson, CJ,Waterhouse, DF,Dawkins, IR,Patle, AK,Horgan, S,Conlon, CM,O'Hanlon, R,Baugh, JA,Ledwidge, MT,McDonald, K (2012) 'Progression of left atrial volume index in a population at risk for heart failure: a substudy of the STOP-HF (St Vincents Screening TO Prevent Heart Failure) trialS'. European Journal of Heart Failure, 14 :957-964. [DOI] [Details]|
|Collier, P,Watson, CJ,van Es, MH,Phelan, D,McGorrian, C,Tolan, M,Ledwidge, MT,McDonald, KM,Baugh, JA (2012) 'Getting to the heart of cardiac remodeling; how collagen subtypes may contribute to phenotype'. Journal of Molecular and Cellular Cardiology, 52 :148-153. [DOI] [Details]|
|Watson, CJ,O'Kane, H,Maxwell, P,Sharaf, O,Petak, I,Hyland, PL,O'Rouke, D,McKnight, J,Canning, P,Williamson, K (2012) 'Identification of a methylation hotspot in the death receptor Fas/CD95 in bladder cancer'. International Journal of Oncology, 40 :645-654. [DOI] [Details]|
|Watson CJ, Phelan D, Xu M, Collier P, Neary R, Smolenski A, Ledwidge M, McDonald K, Baugh J (2012) 'Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-Î² mediated fibrosis'. Fibrogenesis & Tissue Repair, 5 (1). [DOI] [Details]|
|Robinson CM, Watson CJ, Baugh JA (2012) 'Epigenetics within the matrix: A neo-regulator of fibrotic disease'. Epigenetics, 7 (9):987-993. [DOI] [Details]|
|Robinson CM, Neary R, Levendale A, Watson CJ, Baugh JA (2012) 'Hypoxia-induced dna hypermethylation in human pulmonary fibroblasts is ssociated with thy-1 promoter methylation and the development of a pro-fibrotic Phenotype'. Respiratory Research, 13 (1). [DOI] [Details]|
|Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM (2011) 'Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?'. European Journal of Heart Failure, 13 (10):1087-1095. [DOI] [Details]|
|Watson, CJ,Ledwidge, MT,Phelan, D,Collier, P,Byrne, JC,Dunn, MJ,McDonald, KM,Baugh, JA; (2011) 'Proteomic Analysis of Coronary Sinus Serum Reveals Leucine-Rich alpha 2-Glycoprotein as a Novel Biomarker of Ventricular Dysfunction and Heart Failure'. Circulation: Heart Failure, 4 :188-126. [DOI] [Details]|
|Koo, V,Lee, A,Eldin, OS,Watson, C,Hamilton, P,Williamson, K; (2010) 'pcDNA3.1tdTomato Is Superior to pDsRed2-N1 for Optical Fluorescence Imaging in the F344/AY-27 Rat Model of Bladder Cancer'. Aging, 12 :509-519. [DOI] [Details]|
|Watson JA, Watson CJ, McCann A, Baugh J; (2010) 'Epigenetics, the epicenter of the hypoxic response'. Epigenetics : official journal of the DNA Methylation Society, 5 (4):293-296. [Details]|
|McCann A, Watson JA, Watson CJ, McCrohan AM, Woodfine K, Tosetto M, McDaid J, Gallagher E, Betts D, Baugh J, O'Sullivan J, Murrell A, Watson RW, ; (2009) 'Generation of an epigenetic signature by chronic hypoxia in prostate cells'. Human Molecular Genetics, 18 (19):3594-3604. [DOI] [Details]|
|Mak GJ, Ledwidge MT;Watson CJ;Phelan DM;Dawkins IR;Murphy NF;Patle AK;Baugh JA;McDonald KM (2009) 'Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone'. Journal of the American College of Cardiology, 54 (18):1674-1682. [DOI] [Details]|
|O'Kane, HF; Watson, CJ; Johnston, SR; Petak, I; Watson, RWG; Williamson, KE; ; (2006) 'Targeting death receptors in bladder, prostate and renal cancer'. Urology, 175 (2):432-438. [Details]|
|Phelan, D, Watson, CJ, Donnelly, S, Ledwidge, M, Baugh, J, Mcdonald, K, ; (2007) EUR J HEART FAIL Transforming growth factor beta induces collagen type I and alpha smooth muscle actin production in human cardiac fibroblasts , pp.101-101 [Details]|
|Watson, CJ, Phelan, DMJ, Ledwidge, M, Donnelly, S, Mcdonald, K, Baugh, J, ; (2007) EUR J HEART FAIL Increased MMP2 activity following treatment of cardiac fibroblast with Angiotensin II, Alclosterone, Endothelin-1 and TGF beta , pp.101-101 [Details]|
|Watson, C,Collier, P,Horgan, S,Conlon, C,O'Hanlon, R,Ledwidge, M,Baugh, J,McDonald, K (2012) Identification of Serum Biomarkers that Reflect Progressive Cardiac Remodelling. Abstract [Details]|
|Horgan, S,Watson, C,Collier, P,Ledwidge, M,McDonald, K,Baugh, J (2012) Diabetic Hearts Show Increased Lysyl Oxidase Expression. Abstract [Details]|
|Glezeva, N,Voon, V,Watson, C,Ledwidge, M,McDonald, K,Baugh, J (2012) Patients with Hypertension and Heart Failure with Preserved Ejection Fraction Present with Elevated Inflammatory and Alternative Monocyte/Macrophage-Apecific Markers in their Peripheral Circulation. Abstract [Details]|
|Horgan, S,Watson, C,Collier, P,Ledwidge, M,McDonald, K,Baugh, J (2012) A Novel Biomarker and Potential Treatment for Diastolic Dysfunction and Heart Failure. Abstract [Details]|
|Watson, C,Neary, R,Collier, P,Tolan, M,Ledwidge, M,McDonald, K,Baugh, J (2012) Myocardial Tissue Hypoxia is Associated with Changes in the Epigenome. Abstract [Details]|
|Phelan, D,Watson, C,Collier, P,Ledwidge, M,Baugh, J,McDonald, K (2011) STRETCHED INDUCED B-TYPE NATRIURETIC PEPTIDE ALTERS HUMAN CARDIAC FIBROBLAST RESPONSE TO TRANSFORMING GROWTH FACTOR BETA AND MAY BE PROTECTIVE AGAINST MYOCARDIAL FIBROSIS. Abstract [Details]|
|Bates, A,Watson, C,Baugh, J (2011) ROLE OF SERUM AMYLOID P IN FIBROSIS AND DIASTOLIC HEART FAILURE. Abstract [Details]|
|Tea, I,Robinson, C,Watson, C,Baugh, J (2011) IDENTIFICATION OF A FUNCTIONAL HYPOXIA RESPONSE ELEMENT IN THE PROMOTER REGION OF THE DNA METHYLTRANSFERASE 3B GENE; POTENTIAL ROLE IN INFLAMMATORY, FIBROTIC & MALIGNANT DISEASE. Abstract [Details]|
|Watson, CJ,Ledwidge, MT,Phelan, D,Collier, P,Byrne, JC,Dunn, MJ,McDonald, KM,Baugh, JA (2011) LRG: a Novel Biomarker of Ventricular Dysfunction and Heart Failure. Abstract [Details]|
|Glezeva, N,Collier, P,Watson, C,Ledwidge, M,McDonald, K,Baugh, J (2010) ATTENUATION OF MONOCYTE CHEMOTAXIS-A NOVEL ANTI-INFLAMMATORY MECHANISM OF ACTION FOR THE CARDIOPROTECTIVE HORMONE B-TYPE NATRIURETIC PEPTIDE. Abstract [Details]|
|Levendale, AL,Baugh, JA,Watson, CJ (2010) THE EFFECT OF HYPOXIA ON THY-1 EXPRESSION. Abstract [Details]|
|Nelligan, N,Dubourd, M,Robinson, C,Watson, C,Baugh, J (2010) HYPOXIA INHIBITS RNA METHYLTRANSFERASE NSUN2 EXPRESSION IN PRIMARY HUMAN AIRWAY EPITHELIA; AND THE DEVELOPMENT OF A NOVEL ANALYTICAL TECHNIQUE TO ELUCIDATE THE POTENTIAL ROLE OF HYPOXIA IN REGULATING GLOBAL RNA METHYLATION. Abstract [Details]|
|Mak, G,Murphy, NF,Phelan, D,Watson, C,O' Loughlin, C,Baugh, J,Ledwidge, M,Mc Donald, K (2008) The effects of low dose eplerenone on markers of collagen turnover in diastolic heart failure. Abstract [Details]|
|Watson, CJ,Phelan, DMJ,Ledwidge, M,Donnelly, S,Mcdonald, K,Baugh, J,Phelan, DMJ (2007) Increased MMP2 activity following treatment of cardiac fibroblast with Angiotensin II, Alclosterone, Endothelin-1 and TGF beta. Abstract [Details]|
|Phelan, D,Watson, CJ,Donnelly, S,Ledwidge, M,Baugh, J,Mcdonald, K (2007) Transforming growth factor beta induces collagen type I and alpha smooth muscle actin production in human cardiac fibroblasts. Abstract [Details]|
|Robinson, CM,Watson, CJ,Baugh, JA (2012) Epigenetics within the matrix A neo-regulator of fibrotic disease. Reviews [DOI] [Details]|
|Association: Irish Cardiac Society (2006-present), Function/Role: Member|
|Association: European Heart Failure Association (2007-present), Function/Role: Member|
|Association: European Society of Cardiology (2007-present), Function/Role: Member|
|Association: British Society of Cardiovascular Research (2012-present), Function/Role: Member|
|Association: National Cardiovascular and Stroke Research Network (2012-present), Function/Role: Steering committee member|
|Committee : SSRA: Summer Student Rearch Activity|
|Committee : National Cardiovascular and Stroke Research Network|
| Year 2005 Institution: Queen's University Belfast
Qualification: PhD Subject: Epigenetics and response to cancer therapeutics
| Year 2002 Institution: Queen's University Belfast
Qualification: BSc Subject: Biomedical Science
|Reviewer for Funding Agency: Heart Research UK|
Prof Ken McDonald (Consultant cardiologist, National Clinical Lead in Heart Failure, SVUH and Heartbeat Trust): Providing clinical support and a longitudinal biobank of clinical samples. Collaborate on 5 clinical therapeutic studies.
Dr John Baugh: Lung and cardiac fibrosis collaborative projects.
Dr Mark Ledwidge: Commercialisation expertise, MMP inhibitor studies in obesity, diabetes, and heart failure.
Dr Gordon Cooke: Collaborate on projects relating to identification and validation of novel anti-microbial peptides derived from African frog venom.
Prof Seamas Donnelly: Lung fibrosis studies and provides clinical material. Collaborate on novel therapeutic strategies for idiopathic pulmonary fibrosis.
Prof Stephen Pennington: Mass spectrometry expertise for multimarker analysis of heart failure biomarkers.
Dr Amanda McCann: Studies investigating epigenetic regulation in hypoxia
Prof Fionnuala McAuliffe: Animal studies on impact of gestational diabetes on the foetal heart. Biomarker analysis within a clinical gestational diabetes study.
Mr Michael Tolan: Consultant Cardiothoracic surgeon, providing human cardiac tissue samples.
Dr Seamus Giles: Development of a programme to facilitate medical student exposure to laboratory based experimental techniques and enhance critical thinking around medical research, called UCD LabView.
Dr John O'Donoghue (Assistant Director of the Global eHealth Unit, Imperial College London): Collaborations based on improving global health through ICT, eHealth and mHealth strategies.
Dr Charles Mondo (Makerere University, Kampala, Uganda, Africa): Leading Cardiologist in Uganda and is the Vice-Chair of the Uganda NCD Alliance (UNCDA). Dr. Mondo is also the President of the Uganda Heart Research Foundation. Collaborate on Diabetes and Endomyocardial Fibrosis projects.
Dr Robert Ridley (V.C. of Mzuzu University, Malawi, Africa): Diabetes and cardiovascular disease collaborations with a focus on educational strategies and e-Health. This collaboration also includes the development of a e-Health Research Unit in conjunction with ICL.
Dr. John Chipolombwe (Head of Medical Department, Mzuzu Central Hospital, Malawi): Biomarkers for Diabetes and cardiovascular disease
Prof Thomas Thum (Professor and Director of the Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Germany): Disease mechanisms and diagnostic roles for miRNAs in diastolic heart failure and diabetic cardiomyopathy.
Dr David Grieve (Senior Lecturer in cardiovascular Physiology, Queen¿s University Belfast, Northern Ireland): Animal models of heart failure (aortic banding and myocardial infarction).
Dr Patrick Collier and Dr Deborah Koon (Consultant Cardiologists, The Cleveland Clinic Foundation, USA): Providing clinical samples and data, including human left ventricular tissue.
Dr. Mei Zhou and Dr David Orr (School of Pharmacy, Queen¿s University Belfast): Identification and validation of novel therapeutic drug leads derived from African venom samples in collaboration with Makerere University Uganda.
Dr Harry Steins (Sigma Statistical Services, Scotland): Providing statistical support for multimarker analysis of heart failure biochemical and inflammatory disease markers.
Dr Joe Gallagher (General Practitioner Lead for Heart Failure in Ireland): Co-investigator on several projects including, Heart failure, Pre-eclampsia, Endomyocardial fibrosis, and Diabetes in Malawi research projects. Co-Director of Global Health Research.
Dr Helen Enright (Consultant Haematologist, Adelaide and Meath Hospital): Patient identification for a clinical study investigating the impact of demethylating agents on cardiac function.
Dr Osama Sharif (Pathologist, St. James¿ Hospital, Dublin): Pathological assessment of cardiac tissue samples.
Dr John Gilmore (Professor of Pharmaceutical Sciences, Trinity College Dublin): HPLC quantification of circulating biochemical methyl donors. Pro-drug projects.
Non Governmental Organisations
Luke International Norway, Malawi
|My teaching philosophy can be summarised by the acronym RACE: Respect,Approachable, Content, Engagement.|
Enhancement of Teaching
|I have co-developed and currently facilitating a new teaching tool called LabView which is an innovative initiative designed to link student learning and critical thinking, with observational exposure to the diverse array of scientific techniques performed in the School's research laboratories. In a recent survey that I carried out, 90% of our students agreed that observing first hand experimental techniques that are often referred to in lectures and textbooks, would enhance their learning experience. This initiative has resulted in our research staff open their doors with LabView demonstrations.|